### Leuprorelin

**Indication**
Malignant neoplasms of prostate

**INN**
Leuprorelin

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

**EML status history**
First added in 2015 (TRS 994)
Changed in 2021 (TRS 1035)

**Sex**
Male

**Age**
Adolescents and adults

**Therapeutic alternatives**
goserelin (ATC codes: L02AE03)
triptorelin (ATC codes: L02AE04)

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Tags**
- Cancer

**Wikipedia**
Leuprorelin

**DrugBank**
Leuprorelin (Leuprolide)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended goserelin and triptorelin be specified as therapeutic alternatives under the square box listing for leuprorelin on the EML.